Rafael Amado, EVP of R&D and CMO at Allogene Therapeutics, Inc. (ALLO), sold 2,000 shares at $11.44 ($23K) on 2022-07-05, disclosed to the SEC on 2022-07-06.
Scheduled sale ($23k) by EVP of R&D and CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ZLAB | SELL | 2026-03-16 | $110K | — | Filing → |
| ZLAB | SELL | 2026-03-05 | $174K | — | Filing → |
| ZLAB | SELL | 2026-01-02 | $188K | — | Filing → |